How Racemic Epinephrine Shrinks Swollen Airways in Croup

Racemic epinephrine is a nebulized form of adrenaline that contains equal parts of two mirror-image molecules, and it has been a go-to emergency treatment for croup and other causes of upper airway swelling for decades. It works fast, typically producing noticeable relief within 30 minutes, but its effects wear off in roughly an hour and a half to two hours. That short therapeutic window shapes almost everything about how the drug is used in practice, from the observation periods emergency departments enforce to the corticosteroids prescribed alongside it.

What Makes It “Racemic” and How It Shrinks Swollen Airways

Epinephrine exists in two mirror-image forms. The L-form (levorotatory, or left-handed) is the naturally occurring version your body produces during a fight-or-flight response. The D-form (dextrorotatory, or right-handed) is its chemical twin but far less potent at most receptor sites. “Racemic” simply means the solution is a 50/50 mix of both forms. Because only about half of the molecules in a racemic solution are the more active L-form, the effective dose per milliliter is lower than a pure L-epinephrine solution of the same concentration.

When nebulized and inhaled, epinephrine lands directly on the inflamed airway lining. It stimulates receptors on the small blood vessels in that tissue, causing them to constrict. Less blood flow means less fluid leaking into the surrounding tissue, and the swelling shrinks.¹ At the same time, it relaxes smooth muscle in the bronchial tubes, opening up the lower airways. That dual action, vasoconstriction above and bronchodilation below, is what makes it useful for conditions where the airway is narrowed by inflammation.²

Croup Is Where Racemic Epinephrine Earns Its Reputation

Croup, or laryngotracheitis, is the condition most closely associated with racemic epinephrine. When a child’s subglottic airway swells from a viral infection, the hallmark barking cough and stridor (that high-pitched, harsh sound on inhaling) can be frightening. In moderate to severe cases, nebulized racemic epinephrine can cut a child’s croup severity score by two to three points on a standardized scale within 30 minutes, which translates to visibly easier breathing and less stridor.³

The relief, however, is temporary. The vasoconstriction that pulls fluid out of the swollen tissue wears off after roughly 90 to 120 minutes.⁴ When it does, the swelling can return, sometimes to the same level as before treatment. This so-called rebound effect is the reason emergency departments keep children under observation for at least two to three hours after a dose. A child who looks dramatically better at the 30-minute mark may need another treatment or closer monitoring as the drug fades. If a child remains comfortable after that observation window and has received a corticosteroid, many clinicians feel safe sending them home.

Racemic Versus L-Epinephrine

For years, racemic epinephrine was the only formulation widely used for nebulized airway treatment. But because the racemic form was periodically hard to get (it has gone through recurring supply shortages), clinicians began asking whether plain L-epinephrine, which is universally available because it is used for anaphylaxis, cardiac arrest, and dozens of other indications, could do the same job.

The answer, based on head-to-head studies, is yes. A randomized double-blind trial comparing L-epinephrine aerosols with racemic epinephrine aerosols in children with croup found that both produced significant, transient reductions in croup scores and respiratory rates, with no differences between groups in croup score, heart rate, blood pressure, or respiratory rate over time.⁵ The researchers concluded that L-epinephrine is at least as effective and does not carry additional side effects. A Cochrane review found no difference in croup scores between the two formulations at 30 minutes, though one small trial suggested L-epinephrine may hold a slight edge at the two-hour mark.⁶

More recent data reinforces this equivalence. A study comparing L-epinephrine delivered by metered-dose inhaler against racemic epinephrine by nebulizer found no statistical difference in the need for repeat dosing, change in heart rate, return visits within 48 hours, or hospital admission.⁷ This is clinically important because it means that when racemic epinephrine is unavailable or expensive, facilities can substitute L-epinephrine without compromising care. Many hospitals now stock only L-epinephrine and use it interchangeably for croup.

Dosing Considerations

A common question, particularly for parents who have watched their child receive nebulized epinephrine, is whether the dose matters as much as the decision to treat. The standard racemic epinephrine dose for croup is 0.5 mL of a 2.25% solution diluted in normal saline and delivered via nebulizer over about 15 minutes. For L-epinephrine, the typical dose is 0.5 mg/kg of a 1:1000 solution (up to a maximum of 5 mL).

Research on dose-response relationships suggests that within the commonly used range, bigger doses do not necessarily work better. A randomized trial in children with post-extubation stridor compared 0.5, 2.5, and 5 mL doses of L-epinephrine and found no significant difference in symptom improvement across the three groups. The children who received the highest dose, however, did experience a meaningful increase in blood pressure at 40 and 180 minutes after treatment.⁸ That finding is a useful reminder that epinephrine is not a drug where “more is better.” The cardiovascular effects, including a rise in heart rate and blood pressure, scale with the dose even when the airway benefits do not.

Similarly, a placebo-controlled trial comparing low-dose nebulized L-epinephrine against placebo in croup found that both groups showed significant score reductions from baseline by 30 minutes, with no statistical difference between them.⁹ That result has sparked debate about whether the act of sitting a child down with a nebulizer mask, calming them, and delivering humidified air accounts for some of the perceived improvement, particularly in milder cases.

Why Corticosteroids Are Almost Always Given Alongside

Because nebulized epinephrine’s effects fade within a couple of hours, it is almost never used alone. The standard of care for moderate to severe croup pairs it with a corticosteroid, most commonly dexamethasone. The steroid works on a different timeline: it takes several hours to kick in but then reduces inflammation for a day or more, bridging the gap after the epinephrine wears off.

A study of 55 croup patients treated with racemic epinephrine, oral dexamethasone, and mist found that over half had a sustained response and were safely discharged after three hours of observation, with no recurrences of respiratory distress and no return visits.¹⁰ Older research comparing the two therapies head-to-head in hospitalized croup patients found that both dexamethasone and racemic epinephrine reduced symptoms and sped recovery, but dexamethasone was more effective by clinical evaluation at 6 and 12 hours after admission. The study also noted that the added benefit of epinephrine was less pronounced in patients who had already received dexamethasone.¹¹

The practical takeaway is that racemic epinephrine is a bridge therapy. It buys time by rapidly reducing airway obstruction while the slower-acting steroid builds up its anti-inflammatory effect. If a child receives both, the steroid is doing the heavier lifting for long-term symptom control, and the epinephrine’s job is to get through the acute crisis.

Bronchiolitis Is a Different Story

Parents and even some clinicians sometimes assume that if nebulized epinephrine helps croup, it should help other conditions that cause wheezing in young children. Bronchiolitis, usually caused by respiratory syncytial virus (RSV), is the most common of these. But the evidence here points in a different direction.

A large randomized trial published in the New England Journal of Medicine compared inhaled racemic adrenaline to inhaled saline in infants hospitalized with bronchiolitis. Length of stay, need for oxygen, nasogastric-tube feeding, ventilatory support, and clinical score improvement were all similar between the two groups.¹² The American Academy of Pediatrics clinical practice guideline is direct about this: clinicians should not administer epinephrine to infants and children diagnosed with bronchiolitis, rating this a strong recommendation.¹³ The guideline notes that a fixed dosing schedule actually lengthened hospital stays compared to as-needed dosing, and that the drug showed no benefit over placebo in the outpatient setting either.

A Canadian review struck a slightly more nuanced note, recommending against routine use but suggesting it could be considered for infants with severe symptoms as a rescue measure. If given and no improvement follows, further doses are discouraged.¹⁴ The underlying reason for the difference between croup and bronchiolitis is anatomical: croup primarily involves swelling above the vocal cords and in the subglottic space, where vasoconstriction can physically open the airway. Bronchiolitis involves inflammation and mucus plugging deep in the tiny bronchioles, where reducing surface blood flow does much less good.

Post-Extubation Stridor

When a breathing tube is removed after surgery or a stay in the intensive care unit, the airway can swell from the irritation caused by the tube itself. This post-extubation stridor looks and sounds similar to croup, and clinicians have long reached for nebulized epinephrine to treat it. The logic is intuitive: if the drug shrinks mucosal swelling in croup, it should do the same for tube-related swelling.

The evidence here is thinner than many assume. In newborns specifically, a Cochrane review found no evidence either supporting or refuting the use of nebulized racemic epinephrine for post-extubation stridor.¹⁵ In older children, the dose-comparison trial mentioned earlier found that none of the three L-epinephrine dose levels produced significantly better outcomes than the others based on croup score changes, and clinical improvement rates did not differ between groups.¹⁶ The drug is still widely used for this indication because clinicians observe short-term relief, but the randomized evidence supporting it is surprisingly lean. It remains a practice based more on clinical experience and biological plausibility than on strong trial data.

Less Common Uses

Outside the emergency department, epinephrine’s vasoconstrictive properties have found surgical applications. In adenoidectomy (removal of the adenoids), topical adrenaline applied to the surgical site significantly decreased intraoperative bleeding. In a randomized controlled trial, surgeons judged bleeding to be significantly reduced in the adrenaline group, the number of nasal packings needed was halved, electrocautery use dropped, and the procedure itself was about five minutes shorter on average.¹⁷ This is a different route of administration (topical rather than nebulized) and a different clinical rationale, but it underscores how broadly adrenaline’s blood-vessel-constricting ability is exploited in medicine.

Nebulized racemic epinephrine has also been reported in severe acute asthma exacerbations when standard therapies fail. A case report described successful use in a patient whose breathing did not improve with first-line treatments.¹⁸ This is not a standard indication, and the evidence amounts to case-level data rather than controlled trials. It falls into the category of last-resort off-label use when a patient is in extremis.

Side Effects and What to Watch For

Because epinephrine stimulates the cardiovascular system, the most common side effects of nebulized racemic epinephrine are predictable: increased heart rate (tachycardia) and elevated blood pressure. These effects tend to be mild and transient at standard doses, but they are dose-dependent. As the dose-comparison study showed, children receiving the highest nebulized dose had significant blood pressure elevations even though their airways did not improve any more than those on lower doses.¹⁹

Other reported side effects include pallor (from the vasoconstriction), tremor, and occasionally nausea. In children, the tachycardia can be exacerbated by the distress of having a nebulizer mask placed on their face, making it hard to separate the drug’s effect from the child’s anxiety. Serious cardiac arrhythmias are a theoretical risk at very high doses but are exceedingly rare with standard nebulized treatment.

The rebound phenomenon already described is perhaps the most clinically relevant safety concern. It is not a side effect in the traditional sense but rather the natural wearing-off of the drug. A family discharged too early after a single nebulized treatment could find themselves back in the emergency department a few hours later with a child whose breathing has worsened again. This is why the observation period after treatment is considered non-negotiable in most guidelines.

Drug Stability and Shelf Life

An underappreciated issue with epinephrine in any form is chemical degradation during storage. L-epinephrine degrades through two main pathways: it can be oxidized (forming sulfonate byproducts) and it can racemize, meaning the active L-form slowly converts into the inactive D-form over time. A stability study found that the lower acceptable limit set by the US Pharmacopoeia (90% adrenaline content, counting both L- and D-isomers together) was reached after about two years of storage. At that point, the content of the therapeutically active L-isomer had already dropped to around 85%.²⁰ For a racemic formulation that already starts at 50% L-epinephrine, this degradation has less practical impact, since both isomers are present by design. But for L-epinephrine preparations used in anaphylaxis auto-injectors and other emergency settings, it highlights why expiration dates matter and why discolored (yellowish or brown) epinephrine solutions should be discarded.

Supply Shortages and Global Access

Racemic epinephrine has experienced intermittent manufacturing shortages in the United States and other countries, which has practical consequences for emergency departments accustomed to stocking it. During these shortages, the clinical equivalence between racemic and L-epinephrine becomes more than an academic footnote: it is the reason patients still get treated. Current evidence establishes what researchers describe as therapeutic equivalence between the two formulations, though important disparities exist in global accessibility and cost.²¹ In many low- and middle-income countries, racemic epinephrine has never been consistently available, and L-epinephrine has been the default croup treatment for decades. The clinical trials showing equivalence have been reassuring for those settings, confirming that the more accessible formulation is not a compromise.

For hospitals and clinics that do stock racemic epinephrine, the main practical advantage is dosing simplicity. The 2.25% racemic solution comes in a single-use vial, the dose is typically the same for all children regardless of weight (0.5 mL nebulized), and there is less room for calculation errors. L-epinephrine dosing, by contrast, is weight-based and requires dilution, which introduces an extra step under the stressful conditions of treating a child in respiratory distress. Whether that convenience justifies maintaining a separate supply chain for a product with intermittent availability is a decision each institution makes based on its own circumstances.